Prognostic significance of ST3GAL-1 expression in patients with clear cell renal cell carcinoma by unknown
RESEARCH ARTICLE Open Access
Prognostic significance of ST3GAL-1
expression in patients with clear cell
renal cell carcinoma
Qi Bai1†, Li Liu1†, Yu Xia1†, Qilai Long1, Jiajun Wang1, Jiejie Xu2* and Jianming Guo1*
Abstract
Background: Aberrant sialylated carbohydrate synthesis is frequently noted in various cancers. Sialyltransferase
ST3GAL-1, which adds a sialic acid in an α-2,3 linkage to Gal β1,3 GalNAc, preforms an important role in modulating
cellular behaviors. However, little is known about prognostic significance of ST3GAL-1 in clear cell renal cell carcinoma
(ccRCC). In this study, we aimed to investigate the prognostic significance of sialyltransferase ST3GAL-1 and its
correlation with clinical outcomes in patients with ccRCC.
Methods: A total of 286 patients who underwent nephrectomy between 2005 and 2007 in a single academic center
were recruited. Immunohistochemical staining was performed on tissue microarrays to assess the expression level.
Kaplan-Meier method and Cox proportional hazard model were applied to assess the prognostic value of ST3GAL-1.
Nomograms were generated as prediction model for overall survival and disease free survival at 5 and 8 years after
nephrectomy.
Results: The present results show high expression of ST3GAL-1 is associated with reduced overall survival (p = 0.013)
and disease free survival (p = 0.004). In multivariate cox analyses, ST3GAL-1 was defined as an independent prognostic
factor for overall survival (p = 0.006) and disease free survival (p = 0.001). After incorporation into the University of
California Integrated Staging System (UISS) intermediate/high risk group for non-metastatic ccRCC, ST3GAL-1 could
further distinguish patient with dismal prognosis (p = 0.015 and 0.002 for OS and DFS respectively). The nomograms
revealed better predictive accuracy in predicting 5- and 8- year overall survival and disease free survival than the TNM
stage alone.
Conclusions: ST3GAL-1 is an independent adverse prognostic factor for recurrence and survival of patients with
ccRCC.
Keywords: Clear cell renal cell carcinoma, β-Galactoside α-2,3-Sialyltransferase 1, Prognosis, Nomogram, Overall survival,
Disease free survival
Background
Renal cell carcinoma (RCC) is the most common solid
lesion within kidney and accounts for 2–3 % of all can-
cers in adults [1]. The predominant histologic subtype is
clear cell renal cell carcinoma (ccRCC) (70–85 %) [2].
Although most patients with localized tumors can be
cured with surgical therapies, 20–30 % of the patients
without any evidence of metastasis will develop relapse
and/or metastatic RCC in the future [3]. Currently,
TNM stage, Fuhrman grade, and Eastern Cooperative
Oncology Group performance status (ECOG PS) have
been widely used as predictors of clinical outcomes for
patients with RCC. Several outcomes prognostic predic-
tion algorithms like University of California Integrated
Staging System (UISS), which incorporates TNM stage,
Fuhrman grade, and ECOG PS, have been proposed pre-
viously to stratify the clinical outcomes after nephrec-
tomy [4, 5]. But the biological nature of ccRCC is kind
of complex with an unpredictable course; even tumors
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with the comparable stage or the same pathological type
could show a wide variation in biological behavior and
clinical outcomes. The improvement of the predictors of
clinical outcomes for RCC is needed [6, 7].
Change in the structure of glycan chains is one of the
most shared features of the malignant transformation [8].
The oligosaccharide chains of glycoprotein and glycolipid
are often terminated by sialic acids, which play intensely
important role in regulating physiologically and patho-
logically interactions with ligands [9]. In types of cancers,
abnormal high level of sialylated tumor associated carbo-
hydrate antigens are frequently noted [10, 11]. The up-
regulated sialylation may mediate key pathophysiological
events during various steps of tumor progression [12–14].
β-galactoside α-2,3-sialyltransferase 1 (ST3GAL-1), which
catalyzes the addition of sialic acid in an α-2,3 linkage to
Gal β1,3 GalNAc, preforms important role in modulating
cellular behavior. Increasing studies have revealed that the
abnormal activity of ST3GAL-1 contributes to the tumor
progression [10, 15–17]. However, few studies dedicated
to evaluate the expression of ST3GAL-1 and its correl-
ation with ccRCC pathological characters, making the
issue elusive.
In this study, we aimed to investigate the prognostic sig-
nificance of sialyltransferase ST3GAL-1 expression and its
correlation with clinical outcomes in patients with ccRCC.
ST3GAL-1 expression was assessed by immunohistochem-
istry, and nomograms integrating ST3GAL-1 with other
prognostic parameters were generated to refine individual
risk stratification in ccRCC patients.
Methods
Patients
We retrospectively collected 286 patients who underwent
nephrectomy between 2005 and 2007 at Zhongshan Hos-
pital Fudan University (Shanghai, China). Patient records
include TNM stage, Fuhrman grades, histology type, ECOG
PS were extracted from the database of the institution, and
all the data above were accessible. Other clinicopathological
and baseline demographic characters include age, sex,
tumor size, and necrosis were also collected retrospectively.
Patients with localized RCC (n = 271) were treated with ei-
ther nephron spare surgery or radical nephrectomy. Pa-
tients with metastatic RCC (n = 15) at diagnosis received
cytoreductive nephrectomy followed by interferon-α based
immunotherapy. Tumor stage and postoperative histo-
pathological type was determined according to the 2010
AJCC TNM classification [18]. The inclusion criteria were
as follows: (1) the histopathological type proved to be
ccRCC, (2) all the individuals had no history of anticancer
therapy before the nephrectomy, and (3) had no history of
other malignant before. If the histopathology was mostly
necrosis (>80%) or the morphologic features represent a
mixture type of clear cell RCC and other RCC were ex-
cluded from the present study. The UISS predictive model
was applied to all cases to stratify the risk groups. Most
patients underwent regular follow-up every 6 months
or earlier for the first 2 years right after the nephrectomy
and every 12 months thereafter. Clinical Research Ethics
Committee of Zhongshan Hospital, Fudan University had
approved the study and granted permissions to access the
patient records. Written, informed consent was obtained
from each individual enrolled in the study.
Immunohistochemical staining and evaluation
Hematoxylin and eosin-stained slides had been screened
for optimal tumor content before we constructed tissue
microarray (TMA) slides. Two cores were taken from
the formalin-fixed, paraffin embedded surgical speci-
mens with 2.0 mm diameter punch to make sure each
array represented the dominant focus of ccRCC. Immu-
nohistochemical staining was performed on TMA, and
the primary antibody was rabbit polyclonal anti-SIAT4A
antibody (ab96129, Abcam, Cambridge, MA, USA). The
images of stained tissue were captured by the computer-
ized image system composed of an Olympus CCD cam-
era connected to a Nikon eclipse Ti-s microscope. The
immunohistochemistry samples were scanned at high-
Fig. 1 Representative photographs of ST3GAL-1 immunostaining. ST3GAL-1 expression in normal kidney tissue (a); Low ST3GAL-1 expression in
tumor tissue (b); High ST3GAL-1 expression in tumor tissue (c). Original magnification: ×200
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power magnification (×200) and photographed by NIS-
Elements F3.2 software. The staining intensity and extent
were scored by two independent pathologists who were
blind to the clinical outcomes using the integrated optical
density (IOD) calculated by Image‐Pro Plus version 6.0
software (Media Cybernetics Inc., Bethesda, MD, USA).
The intensity score was graded as 0 (negative), 1 (weak), 2
(moderate), and 3 (strong); the extent score was calculated
by the percentage of the positive cells (0–100 %). The
staining intensity and extent were then multiplied to gen-
erate the expression score ranging from 0 to 300. The
score of 210 was selected as the cutoff point of high/low
expression by the X-Tile software (Yale University School
of Medicine, New Haven, CT, USA).
Statistical analyses
The correlation between ST3GAL-1 expression and clin-
icopathological characteristics was analyzed with Fisher’s
exact test, χ2 test or t test. Kaplan-Meier method was ap-
plied to compare overall survival (OS) and disease free
survival (DFS) for groups of low and high expression. Stat-
istical significance was calculated using log-rank test.
Multivariate Cox proportional hazard models were used
to estimate and test the impact of demographic character-
istics, clinical features and ST3GAL-1 expression on over-
all survival and disease free survival. Hazard ratio (HR)
and 95 % confidence interval (CI) were calculated.
The nomograms were generated using R software with
“rms” package (R Foundation for Statistical Computing,
Vienna, Austria). Selection of variables included in no-
mograms was based on statistical significance of multivari-
ate analyses, and tumor size was also included in the
model as continuous variable. For DFS, we divided T stage
variable into T1a and T1b + T2, due to the clinical similar-
ity for metastases after radical nephrectomy [19]. Calibra-
tion plots for 5- and 8- year OS and DFS were generated
to explore the performance characteristics of the predict-
ive model. The Harrell’s concordance indices (c-indices)
were used to measure the prognostic accuracy. All data
analyses above were performed using SPSS version 19.0
(SPSS Inc., IL, Chicago, USA) and R software with “rms”
package (R Foundation for Statistical Computing, Vienna,
Austria). All statistical tests were two sided and consid-
ered significant at two-sided p <0.05 levels.
Results
ST3GAL-1 expression and survival analyses in human ccRCC
The representative images of immunostaining were present
in Fig. 1. The ST3GAL-1 expression was very low or not
detectable in normal kidney tissues (Fig. 1a). The positive
staining of ccRCC predominantly appeared in the cell cyto-
plasm (Fig. 1c). We analyzed a total of 286 patients in the
present study. As Table 1 presented, the mean (SD) age
was 55.0 (13.0) years old and the median follow up was 99
(range 2.63–120.47) months. Thirteen patients had distant
metastasis, and two patients had regional lymph node me-
tastasis at time of surgery. The Kaplan-Meier curves show
that patients with high ST3GAL-1 expression level tend to
have significantly adverse outcomes for OS (p = 0.013,
Fig. 2a) than those with low ST3GAL-1 expression pa-
tients. For patients with localized ccRCC, the differences
Table 1 Associations between ST3GAL-1 expression and
clinicopathological characteristics in patients with ccRCC
ST3gal-1 expression
Characteristics All patients Low High p*
Age (years) 0.656
Mean ± SD 55.0 ± 13.0 54.7 ± 13.6 55.4 ± 11.9
Gender 0.455
Female 90 57 33
Male 196 115 81
T stage 0.913
T1 180 106 74
T2 24 14 10
T3 79 50 29
T4 3 2 1
N stage 1.000
N0 284 171 113
N1 2 1 1
M stage 0.102
M0 273 167 106
M1 13 5 8
TNM stage 0.334
I 176 105 71
II 20 12 8
III 75 49 26




1 31 19 12
2 216 127 89
3 37 24 13
4 2 2 0
Necrosis 0.652
Absent 249 151 98
Present 37 21 16
ECOG PS 0.587
0 198 117 81
≥1 88 55 33
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance
status, ccRCC clear cell renal cell carcinoma
*χ2 test or t test was performed. p < 0.05 was regard as statistically significant
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were still significant in both OS (p = 0.030, Fig. 2b) and
DFS (p = 0.004, Fig. 2c).
Extension of the UISS (non-metastatic) prognostic model
with ST3GAL-1
The UISS (non-metastatic) algorithm performed well in
stratifying the risk group for overall survival and disease
free survival in our ccRCC cohort (p < 0.001). Furthermore,
we sought to investigate whether incorporation of high/low
ST3GAL-1 expression into UISS outcome algorithm would
improve the predictive accuracy by calculating c-index.
In the IR/HR group for localized ccRCC, significant differ-
ence was found in OS (p = 0.015) and DFS (p = 0.002) ac-
cording to the ST3GAL-1 expression (Fig. 3b, d), however
ST3GAL-1 failed to further stratify patients with different
prognosis in UISS LR patients (Fig. 3a, c). The c-indices of
Fig. 2 Kaplan-Meier analyses for overall survival and disease free survival of patients with ccRCC according to ST3GAL-1 expression. Overall survival
according to ST3GAL-1 expression in all ccRCC patients (a); overall survival according to ST3GAL-1 expression in localized ccRCC patients (b); disease
free survival according to ST3GAL-1 expression in localized ccRCC patients (c); p-value was calculated by Log rank test, <0.05 was regarded as
statistically significant
Fig. 3 Kaplan-Meier analyses for overall survival and disease free survival of patients in UISS (non-metastatic) subgroups. Overall survival for patients in
the UISS (non-metastatic) low risk group (a) and intermediate/high risk group (b) according to ST3GAL-1 expression; disease free survival for patients in
the UISS (non-metastatic) low risk group (c) and intermediate/high risk group (d) according to ST3GAL-1 expression; UISS: University of California Los
Angeles Integrated Staging System; p-value was calculated by Log rank test, <0.05 was regarded as statistically significant
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the UISS were 0.65 and 0.63 for OS and DFS respectively,
and improved to 0.69 and 0.68 when ST3GAL-1 was
added. For patients with metastatic ccRCC, we didn’t use
ST3GAL-1 to further refine the UISS (metastatic) algo-
rithm due to the limited individuals.
Multivariate cox regression analyses
To investigate the prognostic impact of ST3GAL-1 on
ccRCC, multivariate Cox regression models were applied
(Table 2). In the multivariate cox models, patients with
higher ST3GAL-1 expression showed a significantly re-
duced OS (p = 0.006) and DFS (p = 0.001) compared with
their counterparts. It was also confirmed that TNM stage
(p < 0.001), Fuhrman grade (p = 0.044), Necrosis (p = 0.045),
and ECOG PS (p = 0.047) were independent prognostic
factors for OS, and T stage (p = 0.003), Fuhrman grade
(p = 0.020) and necrosis (p = 0.015) were independent
prognostic factors for DFS in ccRCC.
Nomogram for predicting overall survival and disease
free survival in ccRCC
Nomograms were generated to predict OS (Fig. 4a) and
DFS (Fig. 5a) at 5 and 8 years after nephrectomy. Total
points were calculated to evaluate the clinical outcomes,
with higher point indicating more adverse outcome
probability. Calibration plots of the nomograms are
shown for 5- and 8- year prediction of OS (Fig. 4b, c)
and DFS (Fig. 5b,c). The Harrell’s c-indices, which indi-
cated the accuracy of the prognostic model, were 0.753
(95 % CI, 0.701–0.805) and 0.745 (95 % CI 0.690–0.800)
for OS and DFS respectively, higher than that of the
TMN stage alone (0.703, 95 % CI: 0.647–0.759 and
0.660, 95 % CI: 0.599–0.721).
Discussion
Glycosylation is quite common in posttranslational mod-
ifications. Almost all the cell surface proteins are glyco-
sylated. The aberrant glycosylation, which is aroused by
the altered expression and activity of glycosyltransferase,
can dramatically affect the glycoprotein and then change
the behavior of cell [20–22]. Sialic acids, a family of nine
carbon sugars are one of the most important monosac-
charide decorating the oligosaccharide chains of several
classes of cell surface and secreted glycan molecules. The
sialylation of the glycan plays very important role in regu-
lating cellular interaction and signal transduction. The
prominent position on cell membrane allows sialoglycan
to effectively participate in cell-cell and cell-extracellular
matrix interaction, including adhesion, migration, and im-
mune recognition [23]. Hypersialylation of glycan in tumor
cells is associated with metastatic behaviors including inva-
sion and enhanced cell survival and correlates with a poor
prognosis for patients with cancer [24].
It is now well-established that altered activity of sialyl-
transferase is one of the key mechanisms to trigger aber-
rant sialylation of glycans and expression of specific tumor
associated carbohydrates in cancer [24]. However, re-
searches focus on the sialylation glycans and sialyltransfer-
ase in ccRCC is now devoid. So in this study, we put our
focus on the sialyltransferase ST3GAL-1, which adds a si-
alic acid in an α-2,3 linkage to Gal β1,3 GalNAc. In the
study, we have revealed the dismal role of ST3GAL-1 and
its impact on patients with ccRCC by survival analyses.
The present results showed that ccRCC patients with
higher level of ST3GAL-1 expression tend to have un-
favorable clinical outcomes than the counterparts. We
also demonstrated that incorporating ST3GAL-1 into
UISS (non-metastatic) could refine the algorithm predic-
tion. In multivariate cox regression model, it was proved
Table 2 Multivariate cox regression analyses for overall survival and disease free survival in ccRCC patients
Variables Overall survival Disease free survival
HR 95 % CI p* HR 95 % CI p*
TNM stage <0.001 0.003
III + IV vs I+II 2.76 1.75–4.34 2.13 1.30–3.51
Fuhrman 0.044 0.020
3 + 4 vs 1+2 1.85 1.02–3.37 2.19 1.13–4.23
Necrosis 0.045 0.015
Present vs Absent 1.81 1.01–3.25 2.16 1.16–4.00
ECOG PS 0.047 0.267
≥1 vs 0 1.61 1.01–2.56 1.35 0.80–2.29
ST3GAL-1 0.006 0.001
High vs Low 1.88 1.20–2.94 2.30 1.40–3.77
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, CI confidence interval, HR hazard ratio
*Data obtained from the Cox proportional hazards model; p <0.05 was regard as statistically significant
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that ST3GAL-1 was an independent prognostic factor for
OS and DFS. Unexpectedly, the N stage in multivariate
analyses was not considered an independent prognostic
factor, which was probably due to the limited number of
N1 individuals (n = 2).
Several studies have elucidated the association of
ST3GAL-1 with tumor progression. Overexpression of
ST3GAL-1 has been reported in types of tumors like colon
and breast cancers [10, 17]. P. Videira found mRNA level
of ST3GAL-1 was significantly higher in malignant bladder
tumor [15]. It has also been confirmed that abnormal
ST3GAL-1 activities could involve in malignant cell trans-
formation and tumor progression. In breast carcinoma,
constitutive ST3GAL-1 expression contributed to an
unfavorable prognosis [16]. In colorectal carcinoma,
ST3GAL-1 expression was associated with lymph node
Fig. 4 Nomogram for predicting 5- and 8-year overall survival in patients with ccRCC. a Nomogram for predicting clinical outcomes integrated
with Fuhrman grade (1/2/3 + 4), TNM stage (I + II/III + IV), tumor size (continuous variable), necrosis (absent/present), ECOG PS (0/≥1), and ST3GAL-1
expression (low/high); b Calibration plot for nomogram predicted and observed 5-year overall survival rate; c Calibration plot for nomogram predicted
and observed 8-year overall survival rate. Line of dashes: ideal model, vertical bars: 95 % confident interval. ECOG PS = Eastern Cooperative Oncology
Group performance status. Higher total point indicated a more adverse outcomes probability
Bai et al. BMC Cancer  (2015) 15:880 Page 6 of 9
metastasis [10]. Previous studies have reported that
EMT, which is essential for tumor progression, is asso-
ciated with altered expression of sialoglycans [25]. Up-
regulation of sialyltransferase and following expression
of sialoglycan is an important step underlying the migratory
phenotype during EMT. Moreover, the proto-oncogene, c-
myc could up-regulate the ST3GAL-1, while the metastasis
suppressor gene nm23-H1 plays an opposite role [25, 26],
indicating the protumoral role of ST3Gal-1 in the develop-
ment and progress of tumors.
Selectins, receptors for sialyl Lewisx (sLex) and sialyl
Lewisa (sLea) expressed on endothelial and blood cells
play an important role in mediating malignant cells dis-
semination [12, 27]. Recent reports have been indicative
of ST3GAL-1’s responsibility for the high expression
of the sialoglycans sLex and sLea [25, 28]. Increased
sLex was reported in liver metastasis of colorectal cancer,
and was associated with poor patient survival and early re-
currence in colorectal carcinoma [27, 29]. The interactions
between selectins with sLex/a result in tumor cell ad-
herence to blood vessels, thus facilitate extravasation
into surrounding tissue, and trigger angiogenesis [30].
After tumors invade into vasculature, malignant cells
with higher ST3GAL-1 were more likely to aggregate
Fig. 5 Nomogram for predicting 5- and 8-year disease free survival in patients with ccRCC. a Nomogram for predicting disease free survival integrated
with T stage (T1a/T1b + T2/T3 + T4), Fuhrman grade (1/2/3 + 4), tumor size (continuous variable), necrosis (absent/present) and ST3GAL-1 expression
(low/high); b Calibration plot for nomogram predicted and observed 5-year disease free survival rate; c Calibration plot for nomogram predicted and
observed 8-year disease free survival rate. Line of dashes: ideal model, vertical bars: 95 % confident interval. Higher total point indicated a more adverse
outcomes probability
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with platelets, and eventually lodge in the small vessels
and distant organs [31]. Thus, it is conceivable that el-
evated sLex/a antigen synthesis caused by ST3Gal-1 in
the tumor favors tumor cells to bind to selectins and
then extricate from the primary tumor enter into blood
stream and promote metastasis formation. This could give
a possible explanation for our finding that patients with
higher ST3GAL-1 expression are more likely to suffer re-
currence and metastasis in the future, and ST3GAL-1 ex-
pression is also an independent risk factor for the disease
free survival in ccRCC. Nowadays, increasing researches
focusing on the sialylated glycan pathways have show a re-
markable effectiveness for tumor therapy in preclinical
and clinical studies [32–34], which might be suggestive
that targeting sialyltransferase could be a novel approach
to deal with RCC some day.
At present, the role of ST3GAL-1 in ccRCC is far from
fully elucidation and need further exploration. Limita-
tions of our study are the retrospective design and rela-
tively small study cohort. A multicenter and prospective
study is needed to validate the results. Moreover, other
sialyltransferase like ST3GAL-3, ST3GAL-4 were not an-
alyzed in the present study and merit further research.
Conclusion
In conclusion, we have confirmed ST3GAL-1 is corre-
lated with unfavorable outcomes and could be used as
an independent prognosticator in patients with ccRCC.
We also developed nomograms for OS and DFS, which
could give a better prediction for patients with ccRCC
after surgery.
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